Showing 1341-1350 of 1484 results for "".
- FDA Approves Expanded Indication for Merck's Keytruda for Treatment of Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-expanded-indication-for-mercks-keytruda-for-treatment-of-advanced-melanoma/2458773/The FDA has approved an expanded indication for Merck’s Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indicat
- Oculus Innovative Sciences Receives FDA Clearance for Microcyn-Based SebDerm Gelhttps://practicaldermatology.com/news/oculus-innovative-sciences-receives-fda-clearance-for-microcyn-based-sebderm-gel/2458780/Oculus Innovative Sciences, Inc. received a new 510(k) clearance from the FDA for the company’s new Microcyn®-based SebDerm Gel. As a prescription product, SebDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrh
- ASDS Awards 10 Clinical Research Grantshttps://practicaldermatology.com/news/asds-awards-10-clinical-research-grants/2458811/The American Society for Dermatologic Surgery (ASDS) has awarded a total of $96,000 to 10 new clinical research projects through its Cutting Edge Research Grant program. This year’s research projects will focus on topics ranging from examining the effectiveness of specific lasers on surgica
- Immune Pharmaceuticals: FDA Accepts IND Application for Bertilimumab for Bullous Pemphigoidhttps://practicaldermatology.com/news/immune-pharmaceuticals-fda-accepts-ind-application-for-bertilimumab-for-bullous-pemphigoid/2458813/Immune Pharmaceuticals, Inc. has indicated that the FDA has accepted the Company's Investigational New Drug (IND) application for its first in class, lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP). This FDA acceptance enables the Company to expand recruitme
- Syneron Appoints Jeff Nardoci as President of North America Body Shaping Grouphttps://practicaldermatology.com/news/syneron-appoints-jeff-nardoci-as-president-of-north-america-body-shaping-group/2458820/Syneron Medical Ltd., a leading global aesthetic device company, appointed Jeff Nardoci as President of its North America Body Shaping Group. In this position, Mr. Nardoci will be responsible for the development and execution of the company's growth strategies for UltraShape and VelaShape. He
- LEO Pharma to Acquire Global Dermatology Portfolio from Astellashttps://practicaldermatology.com/news/leo-pharma-to-acquire-global-dermatology-portfolio-from-astellas/2458818/LEO Pharma A/S and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million. Under the terms of the agreement, the assets and associated respon
- Lumenis UltraPulse Technology is Being Used to Treat Kim Phuc “The Girl in the Picture”https://practicaldermatology.com/news/lumenis-ultrapulse-technology-is-being-used-to-treat-kim-phuc-the-girl-in-the-picture/2458821/Lumenis Ltd.’s UltraPulse laser is being used by Jill Waibel, MD to treat scars on Kim Phuc, a survivor of a Vietnam War bombing in 1972. The UltraPulse was chosen for its effectiveness in laser scar revision therapy that is needed to penetrate deep into the thick scars. Kim Phuc, a
- New Tattoo Survey Shows Tattoo Acceptance Up; Tattoo Regret Still an Issuehttps://practicaldermatology.com/news/new-tattoo-survey-shows-tattoo-acceptance-up-tattoo-regret-still-an-issue/2458826/With nearly 40 percent of Americans ages 18-29 sporting ink, body art has not only become mainstream, but can actually up someone's stock. In a recent Syneron Candela survey, attitudes toward people with tattoos were overwhelmingly positive, being described as artistic and creative (50 percen
- Syneron Candela Announces New FDA Clearance for the CO2RE Systemhttps://practicaldermatology.com/news/syneron-candela-announces-new-fda-clearance-for-the-co2re-system/2458825/The FDA has granted numerous additional indications for use of Syneron Medical Ltd.’s CO2RE CO2 device. This clearance, including more than 90 specific indications in total, significantly expands the business opportunity for CO2RE users for high patient dema
- FDA Approves Yervoy for Adjuvant Treatment for Fully Resected Stage III Melanomahttps://practicaldermatology.com/news/fda-approves-yervoy-for-adjuvant-treatment-for-fully-resected-stage-iii-melanoma/2458829/The FDA approved Bristol-Myers Squibb Company’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1mm who have undergone complete resection including total lymphadenectomy. Th